We have a diversified and balanced clinical development pipeline covering multiple therapeutic areas, including CNS, cardiovascular and immunological disorders, as well as orphan diseases.

We bring new perspectives to the development of innovative compounds, challenging accepted paradigms to answer the questions that matter to patients. Our key assets have the potential to transform treatment in the target indications.

A long-term strategic perspective is vital to ensure that our drugs address important healthcare challenges. A smart company must adopt creative approaches to delivering its medicines to patients.

To maximize the benefit of our pioneering therapies for patients, we will consider strategic partnerships and build our own commercial infrastructure to provide access to our drugs in certain therapeutic fields.

We are building Idorsia with a long-term focus and ambitious aspirations. We will run the company in a responsible and sustainable way. Becoming profitable will provide us with financial independence and secure our future.

Idorsia has the potential to generate significant revenues from product sales once the first of its pipeline candidates has received regulatory approval for commercialization. In the meantime, Idorsia has generated revenue through a milestone payment from its collaboration with Janssen on the co-development and commercialization of aprocitentan; this collaboration could also generate royalty payments. Furthermore, Idorsia could benefit from revenue-sharing payments relating to potential sales of ponesimod.

Idorsia is a high-potential biopharmaceutical company with a balanced portfolio of innovative drugs. As our assets advance and reach the market, there is a need to constantly replenish the pipeline with innovative compounds. This is where our highly productive drug discovery engine creates opportunities.

We are passionate and curious scientists, determined to help patients function better, feel better and live longer. Our drug discovery focuses on creating small molecules that are active on well-selected molecular targets. Knowledge built through the development of drugs active on one target can often benefit projects in several therapeutic areas.

As we want to remain at the cutting edge of science, it is vital that we consider innovative approaches from bench to bedside. We must integrate computational tools and digital technologies at different stages of the drug discovery, development and commercialization process, to maximize our potential and bring breakthrough medicines to patients.

Idorsia will look for creative ways to harness advances in technology to focus on novel targets and use new drug development methods. All functions of Pharmaceutical Development are streamlined to ensure the delivery of technically tailored and high-quality medicines. As the company establishes its commercial infrastructure, we will look for opportunities to use technology to benefit as many patients as possible.